List of Excipients in API pazopanib hydrochloride
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing pazopanib hydrochloride
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | VOTRIENT | pazopanib hydrochloride | 0078-0670 | CELLULOSE, MICROCRYSTALLINE | |
| Novartis Pharmaceuticals Corporation | VOTRIENT | pazopanib hydrochloride | 0078-0670 | FERROSOFERRIC OXIDE | |
| Novartis Pharmaceuticals Corporation | VOTRIENT | pazopanib hydrochloride | 0078-0670 | HYPROMELLOSES | |
| Novartis Pharmaceuticals Corporation | VOTRIENT | pazopanib hydrochloride | 0078-0670 | MAGNESIUM STEARATE | |
| Novartis Pharmaceuticals Corporation | VOTRIENT | pazopanib hydrochloride | 0078-0670 | POLYETHYLENE GLYCOL 400 | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing pazopanib hydrochloride
Detailed excipient profiles for pazopanib hydrochloride
Excipient focus: CELLULOSE, MICROCRYSTALLINE
pazopanib hydrochloride drug variants containing CELLULOSE, MICROCRYSTALLINE
pazopanib hydrochloride drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
pazopanib hydrochloride drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Novugen Pharma (USA) LLC | pazopanib hydrochloride | 82293-022 |
| >Company | >Ingredient | >NDC |
pazopanib hydrochloride drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-0670 |
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-1077 |
| Torrent Pharmaceuticals Limited | pazopanib hydrochloride | 13668-735 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
pazopanib hydrochloride drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-0670 |
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-1077 |
| Novugen Pharma (USA) LLC | pazopanib hydrochloride | 82293-022 |
| >Company | >Ingredient | >NDC |
pazopanib hydrochloride drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | pazopanib hydrochloride | 13668-735 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
pazopanib hydrochloride drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | pazopanib hydrochloride | 13668-735 |
| Novugen Pharma (USA) LLC | pazopanib hydrochloride | 82293-022 |
| >Company | >Ingredient | >NDC |
pazopanib hydrochloride drug variants not containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-0670 |
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-1077 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSES
pazopanib hydrochloride drug variants containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-0670 |
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-1077 |
| >Company | >Ingredient | >NDC |
pazopanib hydrochloride drug variants not containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | pazopanib hydrochloride | 13668-735 |
| Novugen Pharma (USA) LLC | pazopanib hydrochloride | 82293-022 |
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
pazopanib hydrochloride drug variants containing MAGNESIUM STEARATE
pazopanib hydrochloride drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 400
pazopanib hydrochloride drug variants containing POLYETHYLENE GLYCOL 400
pazopanib hydrochloride drug variants not containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 80
pazopanib hydrochloride drug variants containing POLYSORBATE 80
pazopanib hydrochloride drug variants not containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE
pazopanib hydrochloride drug variants containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-0670 |
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-1077 |
| >Company | >Ingredient | >NDC |
pazopanib hydrochloride drug variants not containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | pazopanib hydrochloride | 13668-735 |
| Novugen Pharma (USA) LLC | pazopanib hydrochloride | 82293-022 |
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE K30
pazopanib hydrochloride drug variants containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | pazopanib hydrochloride | 13668-735 |
| Novugen Pharma (USA) LLC | pazopanib hydrochloride | 82293-022 |
| >Company | >Ingredient | >NDC |
pazopanib hydrochloride drug variants not containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-0670 |
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-1077 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A
pazopanib hydrochloride drug variants containing SODIUM STARCH GLYCOLATE TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | pazopanib hydrochloride | 13668-735 |
| Novugen Pharma (USA) LLC | pazopanib hydrochloride | 82293-022 |
| >Company | >Ingredient | >NDC |
pazopanib hydrochloride drug variants not containing SODIUM STARCH GLYCOLATE TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-0670 |
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-1077 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
pazopanib hydrochloride drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-0670 |
| Novartis Pharmaceuticals Corporation | pazopanib hydrochloride | 0078-1077 |
| >Company | >Ingredient | >NDC |
pazopanib hydrochloride drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | pazopanib hydrochloride | 13668-735 |
| Novugen Pharma (USA) LLC | pazopanib hydrochloride | 82293-022 |
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
pazopanib hydrochloride drug variants containing TITANIUM DIOXIDE
pazopanib hydrochloride drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
